Your browser doesn't support javascript.
loading
Safety and efficacy of EUS-guided coil and glue injection for the primary prophylaxis of gastric variceal hemorrhage.
Kouanda, Abdul; Binmoeller, Kenneth; Hamerski, Christopher; Nett, Andrew; Bernabe, Jona; Shah, Janak; Bhat, Yasser; Watson, Rabindra.
Afiliação
  • Kouanda A; Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
  • Binmoeller K; Interventional Endoscopy Services, California Pacific Medical Center, San Francisco, California, USA.
  • Hamerski C; Interventional Endoscopy Services, California Pacific Medical Center, San Francisco, California, USA.
  • Nett A; Interventional Endoscopy Services, California Pacific Medical Center, San Francisco, California, USA.
  • Bernabe J; Interventional Endoscopy Services, California Pacific Medical Center, San Francisco, California, USA.
  • Shah J; Department of Gastroenterology, Oschner Medical Center, New Orleans, Louisiana, USA.
  • Bhat Y; Department of Gastroenterology, Palo Alto Medical Foundation, Palo Alto, California, USA.
  • Watson R; Interventional Endoscopy Services, California Pacific Medical Center, San Francisco, California, USA.
Gastrointest Endosc ; 94(2): 291-296, 2021 08.
Article em En | MEDLINE | ID: mdl-33539908
ABSTRACT
BACKGROUND AND

AIMS:

Gastric variceal bleeding (GVB) is associated with high morbidity and mortality. EUS-guided coil and cyanoacrylate (CYA) injection (EUS-CCI) has been shown to be an effective therapy in acute bleeding and secondary prophylaxis; however, there is a paucity of data on primary prophylaxis.

METHODS:

In this single-center observational study, adult patients with high-risk gastric varices (GV; size >10 mm or cherry red spot) without prior bleeding underwent EUS-CCI for the primary prophylaxis of GVB between June 2009 and December 2019. The primary outcome was post-treatment GVB.

RESULTS:

Eighty patients with a mean variceal size of 22.5 ± 9.4 mm and a mean length of follow-up of 3.0 ± 2.4 years were included. The etiology of portal hypertension was cirrhosis in 71 patients (88.7%) and noncirrhotic in 9 (11.3). The mean model for end-stage liver disease score was 12.3 ± 3.7 in patients with cirrhosis. The mean coil number was 1.5 (range, 1-3) and mean glue volume injected 2 mL (range, .5-5). Technical success was achieved in 100%, 96.7% had EUS confirmation of GV obliteration, and 67.7% were obliterated with 1 treatment session. Post-treatment GVB occurred in 2 patients (2.5%) and adverse events in 4 (4.9%). No deaths related to GVB occurred, and emergent transjugular intrahepatic shunts were not needed during the follow-up period.

CONCLUSIONS:

In patients with high-risk GV, EUS-CCI for primary prophylaxis is highly effective at preventing GVB with a low rate of adverse events. Primary prophylaxis of high-risk GV with coil and CYA glue injection should be considered in centers with the appropriate expertise.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Varizes Esofágicas e Gástricas / Doença Hepática Terminal Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies Limite: Adult / Humans Idioma: En Revista: Gastrointest Endosc Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Varizes Esofágicas e Gástricas / Doença Hepática Terminal Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies Limite: Adult / Humans Idioma: En Revista: Gastrointest Endosc Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos